Abstract 1603P
Background
The LACE index predicts readmission within 30 days. We evaluated the success of this score in oncological patients for whom hospitalisation is a common condition.
Methods
Between February and July 2022, 188 patients hospitalised in the oncology service of a tertiary referral university hospital were retrospectively screened. Patients admitted for chemotherapy and day care procedures, patients who died during hospitalisation, and subsequent hospitalisation within a month were excluded. LACE scores of the patients were calculated using the length of stay, acuity of the admission, Charlson comorbidity index and emergency Department use six months before admission.
Results
A total of 60 patients were included in the study. Thirty-six (60%) of the patients were under 65 years of age. Most of the patients admitted had gastrointestinal system cancer (n=27, 45%) and lung cancer (n=14, 23.3%), respectively. Twenty-two (36.7%) patients were hospitalised due to infection, and 38 (63.3%) were for palliative care. The median hospital stay of the patients was ten days (min-max: 2-65). The median LACE score of the patients was 11.5 (min-max: 6-16). Fifty-two (%86.7) patients had a high LACE score, eight were in the moderate group, and none were in the low-risk group. Thirty-three (63.5%) of 52 patients with high LACE scores were readmitted to the hospital within 30 days. This rate was statistically significantly higher (p = 0.040) than the moderate group (n=2, 25%). While 55.8% of the patient group with a high LACE score died within 90 days, this rate was (37.5%) in the moderate patient group (p = 0.33).
Conclusions
The LACE index predicted one-month readmission in oncology patients but was insufficient to predict one-month death.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05